High-affinity immunoglobulin epsilon receptor-bound Immunoglobulin E complex (FcεRI-IgE complex)

The FcεRI-bound IgE complex is a pivotal molecular assembly on the surface of mast cells and basophils that acts as the master switch for allergic inflammation (Kinet, 1999). It consists of the high-affinity IgE receptor (FcεRI) and its ligand, Immunoglobulin E (IgE), which binds with an exceptionally low dissociation rate (Schulman, 2001). Upon exposure to specific allergens, these complexes are cross-linked, initiating an intracellular signaling cascade that results in the degranulation of mast cells and the release of potent mediators like histamine and cytokines (Gasser et al., 2020). This mechanism is the fundamental driver of diseases such as allergic asthma, chronic spontaneous urticaria, and food allergies (Kinet, 1999). Pharmacological targeting of this complex primarily involves monoclonal antibodies, such as Omalizumab, which bind to free IgE to prevent its association with the receptor, thereby reducing the density of surface-bound IgE over time (Eggel et al., 2014). Newer therapeutic approaches are exploring disruptor molecules designed to actively break the bond between IgE and FcεRI, offering a more direct and rapid method to desensitize effector cells (Eggel et al., 2014). By lowering the concentration of these complexes, therapies can significantly increase the threshold required for allergen-induced cell activation (Schulman, 2001). Monitoring the density of these complexes on basophils serves as a valuable biomarker for assessing the efficacy of anti-IgE treatments (Gasser et al., 2020).

Other names

IgE-FcεRI complexMast cell-bound IgEFc epsilon RI-bound IgEHigh-affinity IgE receptor complex

Inhibition of IgE binding to the high-affinity receptor (FcεRI) by sequestering free IgE; active dissociation of pre-bound IgE from FcεRI; downregulation of FcεRI surface expression on effector cells.